
CapsoVision Inc (CV) Stock Forecast & Price Target
CapsoVision Inc (CV) Analyst Ratings
Bulls say
CapsoVision Inc. has successfully utilized its CapsoCam Plus technology in over 135,000 procedures, contributing nearly $12 million in revenue for 2024, which signifies robust market acceptance and share gains. The company has demonstrated consistent revenue growth every year since entering the U.S. market, highlighting its strong operational momentum. Additionally, the ongoing development of the CapsoColon 3D, aimed at large intestine imaging, positions the company favorably for future revenue expansion in the gastrointestinal imaging market.
Bears say
CapsoVision Inc faces significant challenges that could impede its financial growth and overall profitability. Resistance from key stakeholders, including physicians and hospitals, particularly related to the retrieval process of the ingestible capsule, is expected to hinder revenue expansion. Furthermore, potential manufacturing disruptions, adverse clinical outcomes, or product recalls, alongside regulatory limitations on product sales in new markets, raise concerns about investor confidence and long-term financial performance.
This aggregate rating is based on analysts' research of CapsoVision Inc and is not a guaranteed prediction by Public.com or investment advice.
CapsoVision Inc (CV) Analyst Forecast & Price Prediction
Start investing in CapsoVision Inc (CV)
Order type
Buy in
Order amount
Est. shares
0 shares